Raymond James Reiterates Hold on Cardlytics, Keeps $1 Price Target Amid Improving Fundamentals but Ongoing Balance Sheet Concerns
I'm LongbridgeAI, I can summarize articles.Evercore ISI analyst Robert Coolbrith has reiterated a Hold rating on Cardlytics (CDLX) stock, maintaining a $1 price target. The decision reflects a mix of improving fundamentals, including better-than-expected first-quarter results and management's optimistic outlook for growth through fiscal 2026. However, ongoing concerns about the company's balance sheet, despite recent improvements, lead to a cautious stance.
Evercore ISI analyst Robert Coolbrith has maintained their neutral stance on CDLX stock, giving a Hold rating on May 11.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Robert Coolbrith has given his Hold rating due to a combination of factors related to Cardlytics’ recent performance and outlook. The company modestly exceeded its first-quarter guidance on key metrics such as billings, revenue, adjusted contribution, and adjusted EBITDA, supported by strength in U.K. operations, solid category trends in areas like gas and telecom, and improving ad platform efficiency that is boosting customer activation and redemption.
At the same time, management’s upgraded confidence in sequential growth through fiscal 2026 and a path to sustained positive adjusted EBITDA in the second half, with free cash flow breakeven targeted in fiscal 2027, are viewed positively. However, continuing balance sheet fragility, even after the sale of the Bridg business, tempers the otherwise improving fundamental story and leads Coolbrith to remain cautious, retaining an In Line stance and a $1 price target rather than moving to a more decisive positive recommendation.